Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-I: Introduction01:29

Asthma-I: Introduction

3.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.8K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.4K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.4K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

4.1K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
4.1K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

2
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
2
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

5.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined large and small airway obstruction is associated with increased exacerbation frequency and poorer symptom control in persistent asthma.

The journal of allergy and clinical immunology. In practice·2026
Same author

Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction in severe asthma: a 52-week prospective study.

Expert opinion on biological therapy·2026
Same author

Small Airway Dysfunction May Mediate the Association Between Body Mass Index and Severe Asthma Exacerbations.

The European respiratory journal·2026
Same author

Switching to dupilumab from other biologic therapies in chronic rhinosinusitis with nasal polyps (CRSWNP): a comparison with biologic-naïve patients.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2026
Same author

An Italian Network for the Management of Severe COVID-19 Disease in Respiratory Intermediate Care Units: The PNEUMO-COV-VEN-IT.

Respiration; international review of thoracic diseases·2026
Same author

Integrating single-inhaler triple therapy into global asthma management: clinical breakthroughs and economic realities.

Journal of medical economics·2026

Related Experiment Video

Updated: Apr 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K

Tailored therapy for severe asthma.

Francesco Menzella1, Mirco Lusuardi2, Carla Galeone1

  • 1Department of Cardiac-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, IRCCS- Arcispedale Santa Maria Nuova, Viale Risorgimento 56, 42123 Reggio Emilia, Italy.

Multidisciplinary Respiratory Medicine
|February 12, 2015
PubMed
Summary
This summary is machine-generated.

New biologic drugs, including monoclonal antibodies targeting specific cytokines and receptors, offer improved treatment options for severe asthma and COPD. Identifying patient phenotypes and biomarkers is crucial for selecting the most effective therapy.

Keywords:
AsthmaCOPDCytokinesInflammationMonoclonal antibodies

More Related Videos

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

6.0K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.8K

Related Experiment Videos

Last Updated: Apr 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

6.0K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.8K

Area of Science:

  • Respiratory Medicine
  • Immunology
  • Pharmacology

Background:

  • Severe asthma and COPD patients often experience suboptimal symptom control due to inadequate treatments.
  • Advances in molecular biology and immunogenetics enable the development of targeted therapies.

Purpose of the Study:

  • To review current and emerging biologic drugs for severe respiratory diseases.
  • To highlight the importance of personalized medicine through phenotype and biomarker identification.

Main Methods:

  • Review of existing literature on biologic therapies for asthma and COPD.
  • Discussion of novel monoclonal antibodies and their mechanisms of action.
  • Exploration of diagnostic biomarkers for treatment selection.

Main Results:

  • Omalizumab is the only currently approved biologic drug.
  • Newer monoclonal antibodies target IgE, IL-5, IL-13, TNF-α, IL-1, and C5a.
  • Biomarkers like IgE and periostin aid in treatment selection.

Conclusions:

  • Personalized treatment strategies are essential for optimizing outcomes in severe asthma and COPD.
  • Ongoing research into novel biologic agents promises more effective therapeutic options.
  • Biomarker discovery will further refine patient stratification and treatment selection.